Terms: = Rhabdomyosarcoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
69 results:
1.
de Traux de Wardin H; Dermawan JK; Vanoli F; Jiang SC; Singer S; Chi P; Tap W; Wexler LH; Antonescu CR
JCO Precis Oncol; 2024 Apr; 8():e2300597. PubMed ID: 38603649
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.
Kotowicz B; Dańska-Bidzińska A; Fuksiewicz M; Nasierowska-Guttmejer A; Raczkiewicz D; Gujski M; Piątek S; Bidziński M
Med Sci Monit; 2023 Dec; 29():e941562. PubMed ID: 38058118
[TBL] [Abstract] [Full Text] [Related]
4. The Cytotoxic Effect of Curcumin in rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling.
Salucci S; Bavelloni A; Stella AB; Fabbri F; Vannini I; Piazzi M; Volkava K; Scotlandi K; Martinelli G; Faenza I; Blalock W
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771452
[TBL] [Abstract] [Full Text] [Related]
5. Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function.
Macha SJ; Koneru B; Burrow TA; Zhu C; Savitski D; Rahman RL; Ronaghan CA; Nance J; McCoy K; Eslinger C; Reynolds CP
Cancer Res; 2022 Sep; 82(18):3345-3358. PubMed ID: 35947641
[TBL] [Abstract] [Full Text] [Related]
6. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
Meister MT; Groot Koerkamp MJA; de Souza T; Breunis WB; Frazer-Mendelewska E; Brok M; DeMartino J; Manders F; Calandrini C; Kerstens HHD; Janse A; Dolman MEM; Eising S; Langenberg KPS; van Tuil M; Knops RRG; van Scheltinga ST; Hiemcke-Jiwa LS; Flucke U; Merks JHM; van Noesel MM; Tops BBJ; Hehir-Kwa JY; Kemmeren P; Molenaar JJ; van de Wetering M; van Boxtel R; Drost J; Holstege FCP
EMBO Mol Med; 2022 Oct; 14(10):e16001. PubMed ID: 35916583
[TBL] [Abstract] [Full Text] [Related]
7. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
[TBL] [Abstract] [Full Text] [Related]
8. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract] [Full Text] [Related]
9. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Profile of a Pituitary rhabdomyosarcoma Arising From a Pituitary Macroadenoma: A Case Report.
Lu J; Chen L
Front Endocrinol (Lausanne); 2021; 12():752361. PubMed ID: 34659131
[TBL] [Abstract] [Full Text] [Related]
11. SNAI2-Mediated Repression of
Wang L; Hensch NR; Bondra K; Sreenivas P; Zhao XR; Chen J; Moreno Campos R; Baxi K; Vaseva AV; Sunkel BD; Gryder BE; Pomella S; Stanton BZ; Zheng S; Chen EY; Rota R; Khan J; Houghton PJ; Ignatius MS
Cancer Res; 2021 Nov; 81(21):5451-5463. PubMed ID: 34462275
[TBL] [Abstract] [Full Text] [Related]
12. The fate of paratesticular masses: 13 years' experience in a tertiary referral centre.
Demirel HC; Tokuç E; Eryilmaz OT; Aykanli E; Yavuzsan AH; Ozagari AA; Kirecci SL; Horasanli K
Aktuelle Urol; 2024 Apr; 55(2):148-153. PubMed ID: 33853159
[TBL] [Abstract] [Full Text] [Related]
13. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract] [Full Text] [Related]
14. rhabdomyosarcoma associated with germline tp53 alteration in children and adolescents: The French experience.
Pondrom M; Bougeard G; Karanian M; Bonneau-Lagacherie J; Boulanger C; Boutroux H; Briandet C; Chevreau C; Corradini N; Coze C; Defachelles AS; Galmiche-Roland L; Orbach D; Piguet C; Scoazec JY; Vérité C; Willems M; Frebourg T; Minard V; Brugières L
Pediatr Blood Cancer; 2020 Sep; 67(9):e28486. PubMed ID: 32658383
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of Eribulin Combined with Irinotecan for treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract] [Full Text] [Related]
16. Signaling pathways in rhabdomyosarcoma invasion and metastasis.
Ramadan F; Fahs A; Ghayad SE; Saab R
Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
[TBL] [Abstract] [Full Text] [Related]
17. Genomic Determinants of Clinical Outcomes in rhabdomyosarcoma.
Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
[TBL] [Abstract] [Full Text] [Related]
18. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
[TBL] [Abstract] [Full Text] [Related]
19. Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in tp53-mutated cells.
Meister MT; Boedicker C; Klingebiel T; Fulda S
Cancer Lett; 2018 Aug; 429():19-28. PubMed ID: 29702195
[TBL] [Abstract] [Full Text] [Related]
20. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway.
Kleinsimon S; Longmuss E; Rolff J; Jäger S; Eggert A; Delebinski C; Seifert G
Sci Rep; 2018 Apr; 8(1):5750. PubMed ID: 29636527
[TBL] [Abstract] [Full Text] [Related]
[Next]
